Immunic's Losses Widen Amidst R&D Spend, Liquidity Concerns Mount

Ticker: IMUX · Form: 10-Q · Filed: Nov 13, 2025 · CIK: 1280776

Immunic, INC. 10-Q Filing Summary
FieldDetail
CompanyImmunic, INC. (IMUX)
Form Type10-Q
Filed DateNov 13, 2025
Risk Levelhigh
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001
Sentimentbearish

Sentiment: bearish

Topics: Biotechnology, Clinical Trials, Going Concern, Liquidity Risk, Net Loss, R&D Expenses, Dilution

TL;DR

**IMUX is burning cash fast with a 'going concern' warning; expect more dilution or a complete collapse if they can't raise capital ASAP.**

AI Summary

Immunic, Inc. (IMUX) reported a net loss of $25.579 million for the three months ended September 30, 2025, an increase from $24.368 million in the prior-year period. For the nine months ended September 30, 2025, the net loss widened to $77.872 million from $75.332 million in the same period of 2024. Research and development expenses increased to $62.914 million for the nine months ended September 30, 2025, up from $58.429 million in 2024, reflecting continued investment in its vidofludimus calcium (IMU-838) Phase 3 clinical development for relapsing multiple sclerosis. General and administrative expenses also rose to $16.987 million for the nine-month period, compared to $13.992 million in 2024. The company's cash and cash equivalents stood at $35.132 million as of September 30, 2025, a decrease from $35.668 million at December 31, 2024. Immunic raised $60.661 million from a May 2025 offering of pre-funded warrants and $4.734 million from an April 2025 common stock offering, net of issuance costs, providing crucial financing. However, the company explicitly stated it does not have adequate liquidity to fund operations for at least twelve months without raising additional capital, raising substantial doubt about its ability to continue as a going concern.

Why It Matters

Immunic's widening net loss and explicit 'going concern' warning are critical for investors, signaling significant financial instability and a high risk of dilution or even cessation of operations if additional capital isn't secured. For employees, this raises job security concerns, while customers and patients awaiting potential therapies like IMU-838 face uncertainty regarding the drug's future development. In the competitive biotech landscape, Immunic's precarious financial position could make it challenging to attract partners or compete effectively with better-funded rivals in the neurologic and gastrointestinal disease spaces, potentially impacting market innovation.

Risk Assessment

Risk Level: high — The company explicitly states it has an accumulated deficit of approximately $589.3 million as of September 30, 2025, and does not have adequate liquidity to fund its operations for at least twelve months without raising additional capital. This raises 'substantial doubt about the Company's ability to continue as a going concern,' indicating a severe financial risk.

Analyst Insight

Investors should exercise extreme caution and consider divesting IMUX shares due to the explicit 'going concern' warning and significant cash burn. Potential investors should avoid initiating a position until the company secures substantial, non-dilutive financing and demonstrates a clear path to profitability or sustainable operations.

Financial Highlights

debt To Equity
N/A
revenue
N/A
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$77.872M
eps
N/A
gross Margin
N/A
cash Position
$35.132M
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What is Immunic's current cash position and how long will it last?

As of September 30, 2025, Immunic, Inc. had cash and cash equivalents of approximately $35.1 million. The company explicitly states that these funds are not adequate to fund its operations for at least twelve months from the issuance of the financial statements without raising additional capital.

Why did Immunic's net loss increase in the latest quarter?

Immunic's net loss for the three months ended September 30, 2025, was $25.579 million, an increase from $24.368 million in the prior-year period. This was primarily driven by total operating expenses increasing to $25.993 million from $25.726 million, with general and administrative expenses rising to $5.981 million from $4.356 million.

What are Immunic's primary drug development programs?

Immunic is pursuing clinical development of three orally administered, small molecule programs: vidofludimus calcium (IMU-838) in Phase 3 for relapsing multiple sclerosis, the IMU-856 program for regenerating bowel epithelium, and the IMU-381 program for gastrointestinal diseases.

What is the significance of the 'going concern' warning in Immunic's 10-Q?

The 'going concern' warning indicates that Immunic's management has substantial doubt about the company's ability to continue operating for at least the next twelve months without securing additional funding. This is a critical risk factor for investors, suggesting potential insolvency or significant operational changes if capital is not raised.

How much did Immunic spend on research and development in the first nine months of 2025?

For the nine months ended September 30, 2025, Immunic spent $62.914 million on research and development expenses. This represents an increase from $58.429 million during the same period in 2024, reflecting ongoing investment in its clinical pipeline.

Has Immunic raised any capital recently?

Yes, Immunic raised $60.661 million from an offering of pre-funded warrants in May 2025 and $4.734 million from a common stock offering in April 2025, both net of issuance costs. These proceeds contributed to the $65.518 million in net cash provided by financing activities for the nine months ended September 30, 2025.

What is Immunic's accumulated deficit as of September 30, 2025?

As of September 30, 2025, Immunic, Inc. had an accumulated deficit of approximately $589.3 million. This figure highlights the company's history of operating losses since its inception in 2016.

What are the main risks Immunic faces according to the filing?

Key risks include the failure of clinical trials to meet endpoints, failure to obtain regulatory approval for its product candidates, and the need for substantial additional funding to continue and potentially complete the development and commercialization of its three development programs. The company's inability to secure additional capital could lead to a material adverse effect on operations or cessation of operations.

Where are Immunic's main operations located?

Immunic, Inc. is headquartered in New York City, NY, with its main operations located in Gräfelfing near Munich, Germany. The company also has a subsidiary, Immunic Australia Pty Ltd.

How many shares of Immunic common stock were outstanding on November 11, 2025?

On November 11, 2025, there were 120,284,724 shares of Immunic, Inc. common stock, $0.0001 par value, outstanding. This number reflects the shares issued and outstanding after the reporting period ended September 30, 2025.

Risk Factors

Industry Context

The biotechnology sector, particularly companies focused on novel therapeutics for neurological disorders like multiple sclerosis, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Immunic operates in a competitive landscape with established players and emerging biotechs, where clinical trial success and regulatory approval are paramount for market entry and commercial viability.

Regulatory Implications

Immunic faces significant regulatory risks associated with the development and potential approval of vidofludimus calcium (IMU-838). Failure to meet stringent FDA and EMA requirements for safety and efficacy in its Phase 3 trials could prevent commercialization, while any delays in the regulatory process could further strain the company's limited financial resources.

What Investors Should Do

  1. Monitor cash runway closely.
  2. Evaluate Phase 3 trial progress and data.
  3. Assess dilution impact.
  4. Consider the 'going concern' warning.

Key Dates

Glossary

Vidofludimus Calcium (IMU-838)
A novel, orally available small molecule inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) being developed by Immunic, Inc. (This is the company's lead drug candidate, with significant R&D investment focused on its Phase 3 development for relapsing multiple sclerosis.)
Going Concern
An accounting principle that assumes a company will continue to operate for the foreseeable future. If substantial doubt exists, it must be disclosed. (Immunic explicitly states substantial doubt about its ability to continue as a going concern, a critical warning for investors regarding its financial viability.)
Weighted-Average Common Shares Outstanding
The average number of a company's common shares outstanding over a specific period, adjusted for stock splits and dividends. (A significant increase in this metric indicates substantial dilution of existing shareholders' ownership due to recent equity offerings.)
Dihydroorotate Dehydrogenase (DHODH)
An enzyme involved in the de novo synthesis of pyrimidines, essential for DNA and RNA production. Inhibiting it can modulate immune cell proliferation. (IMU-838 targets this enzyme, which is the scientific basis for its potential therapeutic effects in autoimmune and inflammatory diseases like multiple sclerosis.)

Year-Over-Year Comparison

Immunic's latest 10-Q shows a continued trend of widening net losses, with the nine-month loss increasing to $77.872 million from $75.332 million year-over-year. This is accompanied by an increased cash burn from operations, rising to $66.525 million from $61.803 million. While the company secured significant financing through equity offerings in April and May 2025, its cash position remains precarious, and the weighted-average shares outstanding have nearly doubled, indicating substantial dilution compared to the prior year.

Filing Stats: 4,567 words · 18 min read · ~15 pages · Grade level 14.7 · Accepted 2025-11-13 07:17:05

Key Financial Figures

Filing Documents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Condensed Consolidated Financial Statements (Unaudited)

Item 1. Condensed Consolidated Financial Statements (Unaudited) Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Loss 5 Condensed Consolidated Statements of Stockholders' Equity 6 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 9

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 30

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 47

Controls and Procedures

Item 4. Controls and Procedures 48

- OTHER INFORMATION

PART II - OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 48

Risk Factors

Item 1A. Risk Factors 49

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 49

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 49

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 49

Other Information

Item 5. Other Information 50

Exhibits

Item 6. Exhibits 50 2 IMMUNIC, INC. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) September 30, 2025 December 31, 2024 (Unaudited) Assets Current assets: Cash and cash equivalents $ 35,132 $ 35,668 Other current assets and prepaid expenses 4,141 3,664 Total current assets 39,273 39,332 Property and equipment, net 640 545 Right-of-use assets, net 791 991 Total assets $ 40,704 $ 40,868 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 7,918 $ 7,846 Accrued expenses 19,454 12,913 Other current liabilities 2,707 1,416 Total current liabilities 30,079 22,175 Long-term liabilities Operating lease liabilities 126 264 Total long-term liabilities 126 264 Total liabilities 30,205 22,439 Commitments and contingencies (Note 9) Stockholders' equity: Preferred stock, $ 0.0001 par value; 20,000,000 authorized and no shares issued or outstanding as of September 30, 2025 and December 31, 2024 — — Common stock, $ 0.0001 par value; 500,000,000 shares authorized as of September 30, 2025 and December 31, 2024, and 98,650,590 and 90,150,869 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 9 8 Additional paid-in capital 597,179 525,611 Accumulated other comprehensive income 2,582 4,209 Accumulated deficit ( 589,271 ) ( 511,399 ) Total stockholders' equity 10,499 18,429 Total liabilities and stockholders' equity $ 40,704 $ 40,868 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 IMMUNIC, INC. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 20,012 $ 21,370 $ 62,914 $ 58,429 General and administrative 5,981 4,356 16,987 13,992 Total operating expenses 25,993 25,726 79,901 72,421

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing